NCT02917187View on ClinicalTrials.gov

A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 9, 2016

Primary Completion Date

December 27, 2016

Study Completion Date

January 5, 2017

Conditions
Primary Inherited Erythromelalgia
Interventions
DRUG

BIIB074

Administered as specified in the treatment arm

DRUG

Placebo

Matched placebo

Trial Locations (5)

19152

Research Site, Philadelphia

26505

Research Site, Morgantown

35242

Research Site, Birmingham

75075

Research Site, Plano

06320

Research SIte, New London

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT02917187 - A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia | Biotech Hunter | Biotech Hunter